Arteriocyte, Inc

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.

Alkermes is a worldwide pharmaceutical company that develops controlled, sustained-release injectable drugs using with its trademark ProLease and Medisorb technologies. Located in Massachusetts, the company also develops inhaled formulations from its proprietary pulmonary technology. Alkermes has partnered with Johnson & Johnson to develop Riserpdal Consta, an antipsychotic drug used in the treatment of schizophrenia. Risperdal Consta is approved for sale in more than 50 countries that include the United States, United Kingdom and Germany. In addition to a host of partnered products, the ocmpany is also active in the development of several promising proprietary products, such as Vivitrex, a long-acting injectable form of naltrexone for alcohol dependence. Alkermes is headquartered in Cambridge, Mass.

Manus Biosynthesis Inc., based in Cambridge, MA, specializes in the development of bioalternatives that replace environmentally harmful ingredients, materials, and chemicals traditionally sourced through petrochemical extraction and agricultural practices. By utilizing advanced synthetic biology and engineered cell factories, the company aims to provide more sustainable, cost-effective, and reliable production solutions for a variety of everyday products. The company's proven scale-up platform facilitates the transition to bioalternatives by managing the entire process from cell factory design to biomanufacturing. With a team of multidisciplinary experts, Manus Biosynthesis is committed to delivering high-quality, traceable, and affordable bioingredients while mitigating environmental impacts in the manufacturing sector. Generated from the website